Six companies that operate under the auspices of the ARC Innovation Center at Sheba Medical Center at Tel Hashomer raised a combined total of over $110 million in 2021, the center reported Wednesday.
Follow Israel Hayom on Facebook and Twitter
The ARC (Accelerate Redesign Collaborate) Innovation Center, led by Professor Eyal Zimlichman, who serves as chief innovation and transformation officer at Sheba, seeks to introduce new technologies to the hospital and community ecosystem.
All six companies are based on technology invented and developed out of Sheba, and the center focuses on digital health technologies such as precision medicine, big data, artificial intelligence (AI), predictive analytics, telemedicine and mobile health.
"The ARC Innovation Center has been focusing on ground-breaking, innovative technologies with a prime directive to redesign healthcare. Our commercialization efforts enable us to expand the reach of these technologies and create global impact on a wide scale," Zimlichman explained.
The six Sheba companies that secured investments in 2021 are:
Aidoc, a provider of artificial intelligence solutions that support and enhance physicians' diagnostic power ($66 million). Aidoc's solutions use AI to analyze medical images directly after acquisition and notify radiologists directly in their workflows of cases with suspected findings. Aidoc has seven FDA-cleared solutions and has won numerous awards including the prestigious UCSF 'Best New Health Application of AI' award and TIME's 50 most genius companies.
Subscribe to Israel Hayom's daily newsletter and never miss our top stories!
BELKIN Laser, a clinical-stage medical device company developing a disruptive automated one-second laser treatment for glaucoma ($13.75 million). Developed by Prof. Michael Belkin, the camera-guided system enables precise contact-free procedure through a sophisticated image processing algorithm that automatically defines the treatment location and tracks the movement of the eye.
Starget Pharma, a start-up biopharmaceutical company that develops products for the diagnosis and targeted treatment of cancer through radioactive radiation ($10 million). Starget develops unique molecules that serve as a vector for selectively transferring imaging materials and treatment to the tumor tissue. Starget's leading research product is a somatostatin-like peptide based on a technology that developed by Sheba Hospital and Tel Aviv University that is licensed exclusively to the company.
Append Medical, developer of the next generation transcatheter Left Atrial Appendage (LAA) closure system ($7.6 million). The Append Medical procedure is designed to prevent blood clot leakage by achieving complete LAA closure, avoid device-related thromboembolism by leaving minimal foreign material at the closure site, while being a simple procedure with fewer LAA pre-procedure measurements. The Append Medical solution is in pre-clinical in-vivo trials phase and is intended to become a differentiated solution in the LAA closure market, which is estimated to reach $25 billion within several years.
Innovalve Bio Medical, an early-stage medical-device company developing catheter-based heart valve therapies ($7.2 million). The company grew out of inventions and patents developed by Sheba experts Professor Ehud Raanani, director of Sheba's Cardiovascular and Thoracic Center, and Dr. Boris Orlev, head of the Sheba's Mitral Valve Surgery Unit. Innovalve has developed an artificial mitral valve that can be replaced using a minimally invasive catheter to help treat patients with heart disease. The company has achieved successful results in experiments on animals and has received US-FDA approval for a US clinical trial, as well as approval in other territories.
TechsoMed, a miotech company that is developing BioTrace, the world's first real-time monitoring and control systems for ablation procedure ($7 million). The technology is applicable to multiple fields such as oncology (tumor ablation), cardiology (heart arrhythmia) and pain management (radiofrequency neurotomy) technology. The breakthrough technology brings disruptive improvement to thermal ablation through real time AI and image analysis by interfacing with a standard ultrasound device.
Dr. Sylvie Luria, CEO of Sheba's Technology Transfer Company, which handles ARC's commercialization efforts, said, "The quality of innovation at Sheba has earned the trust of healthcare innovators and industry alike. Moreover, the funding of six companies this year is a testament to investor confidence in Sheba-developed innovations, which aim to solve complex clinical challenges and make healthcare systems more efficient."
"Reaching $1 billion in investments in ARC technologies over a decade is a milestone, but the impact of these investments in improved healthcare delivery and patient outcomes is exponentially greater," Luria noted.
